Trial results for a study (NCT04765059) evaluating chemotherapy plus Osimertinib against chemotherapy plus placebo in patients with non-small cell lung cancer (NSCLC) were posted on ClinicalTrials.gov on 2026-01-13. This update provides new data for clinicians, researchers, and patient advocates interested in evolving treatment strategies for NSCLC.
Background
The study, identified by its external ID NCT04765059, was designed to evaluate the efficacy and safety of chemotherapy in combination with Osimertinib. This regimen was compared against chemotherapy combined with a placebo in patients diagnosed with non-small cell lung cancer (NSCLC).
What this means
The posting of these trial results offers new information regarding the potential role of Osimertinib when administered in combination with chemotherapy for patients with NSCLC. Clinicians and prescribers can now access and review these findings, which may contribute to a broader understanding of therapeutic options and inform future treatment decisions for individuals affected by this condition.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a comprehensive public registry and results database for clinical studies. The results for the study NCT04765059, titled "A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)," were posted on 2026-01-13.